The Filing Desk

Hyperfine

HYPR · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

HYPR · Last close · November 19, 2026
$0.52
Value Hyperfine yourself

Hyperfine's revenue rose 5.2% to $14 million in fiscal 2025. Its operating margin was −273.4%, up from −335.3% a year earlier. Free cash flow was −$29 million. The diluted share count rose 13.0%.

Hyperfine, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 18, 2026 · 0001193125-26-114044 Updated
Revenue
$14M
5.2%
Operating margin
−273.4%
61.9 pts
Net income
−$36M
 
Free cash flow
−$29M
 
Return on equity
−79.0%
18.0 pts
Market cap
$56M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Hyperfine does

Hyperfine makes the Swoop system, a portable MRI scanner for the brain. MRI, or magnetic resonance imaging, takes pictures of the inside of the body without radiation. Conventional MRI machines are large, cost a lot and need special rooms and trained staff; the Swoop works at a much weaker magnetic field, can be wheeled to a patient's bedside, and is run from an iPad. It uses artificial intelligence software, which Hyperfine calls Optive AI, to clean up its images. A full brain scan takes around 25 minutes on average.

Hyperfine sells the scanner to hospitals and other care providers, mainly in the United States, together with an annual software, service and support agreement. Its first customers used it mostly in intensive care for children and adults, and it is now also selling it to neurology offices outside hospitals. The US Food and Drug Administration first cleared the Swoop in 2020 and has cleared new versions of its hardware and software since, most recently in December 2025. It is also approved for sale in the European Union, the United Kingdom, Canada, Australia, New Zealand and India.

A single contract manufacturer, Benchmark, assembles and supplies its finished products. Hyperfine had 102 full-time employees in February 2026, almost all in the United States.

Its biggest risks, as it describes them

  • It has a history of losses and may not reach meaningful revenue or profit.
  • Doctors and hospitals may not adopt its scanner, a new kind of product in a market that is changing fast.
  • Its reliance on one contract manufacturer and a few suppliers to build its scanners.
  • It may need to raise more money to fund sales, research and new products.
  • Recalls or failing product quality standards could damage its reputation and cost it customers.
From Hyperfine's annual report on Form 10-K, filed March 18, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Hyperfine lost money in fiscal 2025: a net loss of $36 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments188118753835
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio12.6x14.6x10.1x6.2x4.3x
Quick ratio12.3x14.1x9.4x5.5x3.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Hyperfine's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Hyperfine says to expect

  • Full year 2026: revenueManagement continues to expect revenue for the full year 2026 to be approximately $20 to $22 million, representing 55% growth at the midpoint as compared to full year 2025.
  • Full year 2026: net cash burnManagement continues to expect net cash burn 1 for the full year 2026 to be approximately $26 to $28 million, representing a 10% decline at the midpoint as compared to full year 2025.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 9, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Hyperfine shares on the open market, and 2 insiders sold $46,399.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 24, 2026Brett HaleCFO and CAOSold7,345$0.85$6,243Form 4
May 26, 2026Thomas TeisseyreChief Operating OfficerSold6,047$1.65$9,978Form 4
Mar 23, 2026Brett HaleCFO and CAOSold24,188$1.21$29,267Form 4
Feb 13, 2026Thomas TeisseyreChief Operating OfficerSold821$1.11$911Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−324.4%−286.9%−209.6%
Altman Z''2.41−11.00−16.31
Accruals ratio−2.1%−2.5%−13.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rosePassPassPass
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Hyperfine side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
HyperfineFY255.2%−273.4%−214.8%———
CapsoVisionFY2515.3%−188.2%−169.3%———Compare
Nano-X ImagingFY2515.4%−600.8%−345.6%———Compare
ElutiaFY25−15.0%−218.9%−379.8%———Compare
Profound MedicalFY2550.7%−256.3%−238.4%−304.9%—5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue027111314
Revenue growth—408.8%355.5%61.9%16.8%5.2%
Gross profit−0−11567
Research and development152628222218
Operating income−24−65−74−48−43−37
Net income−23−65−44−44−41−36
Diluted EPS (US$)−15.38−17.57−1.04−0.62−0.56−0.43
Diluted shares (millions)2470717282
Cash flow
Cash from operations−22−47−72−42−39−28
Capital expenditure231101
Free cash flow−23−50−73−43−39−29
Dividends paid000000
Share buybacks000000
Acquisitions000000
Stock-based compensation1711543
Balance sheet at fiscal year end
Cash and short-term investments63188118753835
Debt incl. finance leases0—————
Total assets72202134945955
Total liabilities41610101014
Shareholders' equity−61186124844941
Margins and ratios
Gross margin−162.2%−78.0%13.3%43.1%45.7%49.8%
Operating margin−7,990.1%−4,336.1%−1,084.2%−436.1%−335.3%−273.4%
Net margin−7,968.4%−4,335.0%−649.2%−401.0%−315.9%−262.3%
Free cash flow margin−7,854.8%−3,335.1%−1,070.2%−386.3%−303.7%−214.8%
Rule of 40 (growth + FCF margin)—−2,926.2%−714.7%−324.4%−286.9%−209.6%
Return on capital——————
Return on equity—−103.6%−28.6%−42.5%−61.0%−79.0%
Return on assets—−47.3%−26.3%−38.8%−53.2%−62.3%
Net debt to EBITDA——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Hyperfine's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Hyperfine.